Assignee: Cancer Research Campaign Technology Limited

Location: London, GB
No. of patents: 53

Browse patents
Browse applications

Number	Title	Issue Date
7429578	Tricyclic inhibitors of poly(ADP-ribose) polymerases Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ...	09/30/2008
7018791	Binding complexes The present invention relates to binding members that are capable of binding to and effecting the function of proteins useful in facilitating folding of large polypeptides. The present invention particularly relates to the chaperone CCT. The invention provides mater...	03/28/2006
6977298	Tricyclic inhibitors of poly(ADP-ribose) polymerases Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ...	12/20/2005
6852755	Nitrogen mustard compounds and prodrugs therefor This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo,...	02/08/2005
6677345	Cyclin dependent kinase inhibitors A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compou...	01/13/2004
6531097	Measuring the concentration of a substance A system for measuring the concentration of an assay substance comprising a sensor having an optical fiber (10) on one end of which is coated a body (22). A fluorophor is dispersed within the body (22), the fluorescent activity of which is altered in rela...	03/11/2003
6521405	Cell-free replication system and uses thereof The invention relates to improvements in cell-free systems for initiating DNA replication under cell cycle control. The system comprises a synchronous population of G1 nuclei which have been released from G0; and S phase cytosol. In a preferred aspect, a ...	02/18/2003
6380157	Method of treatment using papillomavirus L2 protein The L2 protein of papillomavirus (particularly BPV-2 and BPV-4) has been cloned as a fusion protein with beta-galactosidase and GST; both as the whole protein and as fragments. Vaccination of calves is found to have both a prophylactic effect in tumour pr...	04/30/2002
6303618	Cyclin dependent kinase inhibiting purine derivatives Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclo...	10/16/2001
6303323	Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Ta...	10/16/2001
6277880	Chemical compounds Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions....	08/21/2001
6255070	Folding protein complexes Nucleic acid encoding subunits of a polypeptide folding complex containing TCp-1 is useful in expression of the subunits for assembly of the complex in vitro or in vivo. The complex promotes folding of polypeptides, such as tubulin, e.g., following recomb...	07/03/2001
6225463	Synthesis of new ଲ-lactams The object of the present invention is the development of new chiral auxiliaries for improved ଲ-lactam formation that control both the diastereoselectivity of ଲ-lactam formation and which can be removed without destruction of the sensitive aze...	05/01/2001
6174532	L2 immunogenic peptides of papillomavirus The N-terminal region of bovine papillomavirus (BPV-4) L2 protein includes three immunogenically active epitopes. Two of these epitopes have substantial sequence homology to human papillomavirus (HPV) types. The BPV and HPV sequences are used to produce v...	01/16/2001
6156744	DT-diaphorase directed anti-tumor agents The present invention relates to a novel benzoquinone, 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone and its esters. The compounds can be used to treat tumors exhibiting elevated levels of the enzyme DT-diaphorase....	12/05/2000
6130237	Condensed N-aclyindoles as antitumor agents The invention provides compounds of general formula (I), wherein: X is halogen or OSO2 R, where R represents H or is unsubstituted or hydroxy-or amino-substituted lower alkyl; Y is a nitro or amine group or a substituted derivative thereof; W i...	10/10/2000
6107042	Cell-free system for initiation of DNA replication A cell-free system for initiating DNA replication under cell cycle control includes S phase cytosol or a fraction thereof in which are incubated G1 phase nuclei, which are co-incubated with S phase nuclei or a fraction thereof and/or cyclins A and/or E co...	08/22/2000
6096724	Pyrimidine derivatives and guanine derivatives, and their use in treating tumor cells The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II ##STR1## wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fus...	08/01/2000
6066457	Global amplification of nucleic acids Nucleic acid starting material composed of a collection of single stranded nucleic acid molecules is anchored and processed by a direction random printing method to produce a mixture of shorter random size DNA molecules well-suited for achieving substanti...	05/23/2000
6045997	Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof The identification and sequencing of the BRCA2 gene is disclosed as well as the amino acid sequence of the corresponding BRCA2 polypeptides. BRCA2 alleles including those with mutations in the BRCA2 gene which are associated with a predisposition to devel...	04/04/2000
6042827	Anti-idiotypic antibody induction of anti-tumor response Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions t...	03/28/2000
6034246	2-arylbenzazole compounds There are disclosed herein 2-phenylbenzazole compounds having a 3'-substituent and a 4'-NR2 R6 substituent in the phenyl group where R5 and R6 are each hydrogen or alkyl, or where the $'-NR5 R6	03/07/2000
6025340	Surface expression of enzyme in gene directed prodrug therapy The invention provides a two component system for use in association with one another comprising: (a) a vector capable of expressing an enzyme at the surface of a cell; and (b) a prodrug which can be converted into an active drug by said enzyme, useful in the ...	02/15/2000
6020309	Pharmaceuticals based on papillomaviruses The invention provides pharmaceutical formulations for Immunizing against papillomavirus tumors or lesions. Formulations may be selected from the group consisting of: (i) a formulation which comprises a papillomavirus (PV) L2 protein or fragment thereof t...	02/01/2000
6004550	Intracellular expression of carboxypeptidase G2 in a nitrogen mustard prodrug system The invention provides a two component system for gene-directed enzyme prodrug therapy which comprises: (a) a vector which encodes a carboxypeptidase which is expressed within a cell; and (b) a prodrug which can be converted into an active drug by said ca...	12/21/1999
6005002	Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production The invention provides compounds of formula (I) and (II) wherein X and Y are independently chlorine, bromine, iodine, a mesyl group CH3 SO3 or a tosyl group OSO2 phenyl (wherein phenyl is optionally substituted by 1, 2, 3,...	12/21/1999
5977065	Bacterial nitroreductase for the reduction of CB1954 and analogues thereof to a cytotoxic form A prodrug of the formula (I): ##STR1## where R1 is a group such that the compound R1 NH2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of t...	11/02/1999
5972643	Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor Polynucleotide molecules encoding CTCF are isolated and purified and sequenced. The CTCF proteins and antibodies thereto can be used to identify mutant CTCFs in methods of diagnosis....	10/26/1999
5958721	Methods for screening of substances for therapeutic activity and yeast for use therein Methods of screening for substances which affect mammalian MAP kinase pathways, both inhibitors and activators, are provided. Substances identified using the methods as having such an effect are candidate pharmaceuticals for use in treatment of cancer, in...	09/28/1999
5958971	Chemical compounds Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalyzed reactions....	09/28/1999
5958682	Bacterial nitroreductase gene-prodrug system A system is disclosed which comprises: (i) a viral vector comprising a nucleotide sequence encoding a nitroreductase, which nitroreductase is capable of converting a prodrug into a cytotoxic drug; and (ii) a prodrug capable of being converted into a cytot...	09/28/1999
5929046	Pyrimidine and purine derivatives and their use in treating tumour cells The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II ##STR1## wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fus...	07/27/1999
5874431	Benzazole compounds There are disclosed herein benzazole compounds, exemplified by 2-(4-aminophenyl)benzothiazole and analogues or salts thereof, which exhibit very significant selective cytotoxic activity in respect of tumor cells, especially breast cancer cells, and which ...	02/23/1999
5869053	5T4 antigen from human trophoblasts A new glycoprotein 5T4 has been identified in human trophoblast. The antigen and fragments thereof and, more particularly, antibodies that recognise the antigen or fragments thereof are of value in relation to cancer diagnosis and treatment, particularly ...	02/09/1999
5843143	Light source An apparatus for biological treatment comprises a body, a light source inside the body, a concave mirror mounted in an axial guide on a side of the body, an optical filter on the opposite side in an opening, a fan between the source and the concave mirror...	12/01/1998
5811454	4-amino-fluorobenzamides and their use as cytotoxic prodrugs The invention provides a compound which is a 3-fluorobenzamide of the formula (A) ##STR1## wherein R-NH is the residue of an ଱-amino acid R-NH2 or oligopeptide R-NH2, and M is a nitrogen mustard group of the formula #...	09/22/1998
5780585	Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form A prodrug of the formula (I): ##STR1## where R1 is a group such that the compound R--NH2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula ...	07/14/1998
5770731	Improvements relating to prodrugs A prodrug of the general formula FTLi-(PRT)m, where m is an integer from 1 to 5; FTLi is a ras inhibitor such as a farnesyltransferase inhibitor compound, such as Ia, Ib, Ic; and PRT represents m protecting groups or a precursor thereof, such as compound ...	06/23/1998
5750782	Nitroaniline derivatives and their use as anti-tumour agents The invention provides nitroaniline derivatives represented by general formula (1) where the nitro group is substituted at any one of the available benzene positions 2-6; where R and A separately represent the groups NO2, CN,COOR1, C...	05/12/1998
5728868	Prodrugs of protein tyrosine kinase inhibitors A compound which comprises a prodrug of a protein tyrosine kinase inhibitor (PTKi) linked to a protecting group which is capable of being cleaved from the compound to release the PTKi, said PTKi prodrugs including tyrphostins, of formula (I), ##STR1#...	03/17/1998

«First «Previous1 2 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Cancer Research Campaign Technology Limited